VIM0423

DRUG2 trials

Sponsors

Vima Therapeutics

Conditions

DystoniaPARKINSON DISEASE (Disorder)

Phase 2

A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia

RecruitingNCT07304089

Vima TherapeuticsDystonia

Start: 2026-02-05End: 2027-05-01Target: 100Updated: 2026-09-15

A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy

RecruitingNCT07804615

Vima TherapeuticsPARKINSON DISEASE (Disorder)

Start: 2026-09-01End: 2027-06-01Target: 80Updated: 2026-09-11